🔎 Trials Near Me

Beranda › Glioma › Massachusetts

Uji klinis Glioma di Massachusetts

20 studi untuk Glioma mencari peserta di lokasi di Massachusetts.

Kota di Massachusetts

Teks studi resmi (Bahasa Inggris)

MCT for the Harvard/UCSF ROBIN Center

  • Brigham and Women's Hospital, Boston
Menerima peserta
Semua usia · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06000787

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05099003

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07326566

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  • Dana Farber Cancer Institute., Boston
Menerima pesertaFase 1/2
Hingga usia 25 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04094610

Targeted Pediatric High-Grade Glioma Therapy

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaStudi observasional
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

  • Susan Chi, Boston
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT05303519

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05096481

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

  • Research Site, Boston
Menerima pesertaFase 1/2
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT05417594

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • Tufts Medical Center, Boston
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 8 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05503797

CARv3-TEAM-E T Cells in Glioblastoma

  • Massachusetts General Hospital Cancer Center, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT05660369

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase awal 1Sukarelawan sehat diterima
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT05843253

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06810544

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  • Dana-Farber Cancer Institute, Boston
Menerima pesertaFase awal 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 18 Mar 2026 · NCT04655404

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

  • Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston
Menerima pesertaFase 1
12 Months – 18 Years · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT04943848

CUE-102 in Recurrent Glioblastoma

  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mar 2026 · NCT06917885

NeuroPathways Intervention for Brain Tumor Patients

  • Massachusetts General Hospital Cancer Center, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Des 2025 · NCT05976490

ASCENT Intervention for Brain Tumor Patients

  • Massachusetts General Hospital Cancer Center, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2025 · NCT06099743

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

  • Massachusetts General Hospital, Boston
Menerima pesertaStudi observasional
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 22 Feb 2024 · NCT06118723

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.